These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 34331561)

  • 21. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival.
    Gemmati D; Ongaro A; Tognazzo S; Catozzi L; Federici F; Mauro E; Della Porta M; Campioni D; Bardi A; Gilli G; Pellati A; Caruso A; Scapoli GL; De Mattei M
    Haematologica; 2007 Apr; 92(4):478-85. PubMed ID: 17488658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
    Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
    J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Suh KW; Kim JH; Kim DY; Kim YB; Lee C; Choi S
    Ann Surg Oncol; 2006 Nov; 13(11):1379-85. PubMed ID: 17009149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylenetetrahydrofolate reductase polymorphism is associated with folate pool in gastrointestinal cancer tissue.
    Kawakami K; Omura K; Kanehira E; Watanabe G
    Anticancer Res; 2001; 21(1A):285-9. PubMed ID: 11299748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.
    Monte N; Pantoja KBCC; Rodrigues JCG; de Carvalho DC; Azevedo TCB; Pereira EEB; de Assumpção PP; Dos Santos SEB; Fernandes MR; Dos Santos NPC
    Mol Genet Genomic Med; 2021 Jul; 9(7):e1694. PubMed ID: 34050721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.
    Cecchin E; Perrone G; Nobili S; Polesel J; De Mattia E; Zanusso C; Petreni P; Lonardi S; Pella N; D'Andrea M; Errante D; Rizzolio F; Mazzei T; Landini I; Mini E; Toffoli G
    Pharmacogenomics J; 2015 Jun; 15(3):219-25. PubMed ID: 25331073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
    Toffoli G; Cecchin E
    J Chemother; 2004 Nov; 16 Suppl 4():31-5. PubMed ID: 15688606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of pharmacogenomics in the individualization of chemotherapy for gastrointestinal malignancies.
    McLeod HL; King CR; Marsh S
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S43-7. PubMed ID: 15212705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
    Falvella FS; Luoni M; Cheli S; Fava S; Cergnul M
    Chemotherapy; 2017; 62(5):323-326. PubMed ID: 28614820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Cohen V; Panet-Raymond V; Sabbaghian N; Morin I; Batist G; Rozen R
    Clin Cancer Res; 2003 May; 9(5):1611-5. PubMed ID: 12738713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
    Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
    Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic Diversity of Drug-Related Genes in Native Americans of the Brazilian Amazon.
    Fernandes MR; Rodrigues JCG; Maroñas O; Latorre-Pellicer A; Cruz R; Guerreiro JF; Burbano RMR; de Assumpção PP; Ribeiro-Dos-Santos A; Dos Santos SEB; Carracedo A; Dos Santos NPC
    Pharmgenomics Pers Med; 2021; 14():117-133. PubMed ID: 33519226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single Nucleotide rs760370 Polymorphism at the Main Ribavirin Transporter Gene Detection by PCR-RFLP Assay Compared with the TaqMan Assay and Its Relation to Sustained Virological Response in Chronic HCV Patients Treated with Pegylated Interferon-Ribavirin Therapy.
    Fouad R; Zachariah K; Khairy M; Khorshied M; Ezzat W; Sheta MM; Heiba A
    J Interferon Cytokine Res; 2017 Feb; 37(2):90-96. PubMed ID: 28207300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.
    Davis LA; Polk B; Mann A; Wolff RK; Kerr GS; Reimold AM; Cannon GW; Mikuls TR; Caplan L
    Clin Exp Rheumatol; 2014; 32(3):324-32. PubMed ID: 24447348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.
    Lee KH; Chang HJ; Han SW; Oh DY; Im SA; Bang YJ; Kim SY; Lee KW; Kim JH; Hong YS; Kim TW; Park YS; Kang WK; Shin SJ; Ahn JB; Kang GH; Jeong SY; Park KJ; Park JG; Kim TY
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):843-51. PubMed ID: 23314736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.
    Etienne-Grimaldi MC; Francoual M; Formento JL; Milano G
    Pharmacogenomics; 2007 Nov; 8(11):1561-6. PubMed ID: 18034621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.